DYNE THERAPEUTICS INC. - COMMON STOCK

Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

06 Sep 2022 06:00:01 By Nasdaq GlobeNewswire

Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development

29 Aug 2022 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

10 Aug 2022 06:30:41 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

04 Aug 2022 06:30:01 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

12 Jul 2022 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

05 Jul 2022 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

03 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown

16 May 2022 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

02 May 2022 15:05:01 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

10 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors

03 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy

18 Jan 2022 07:00:01 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

05 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy

02 Dec 2021 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

04 Nov 2021 06:30:01 By Nasdaq GlobeNewswire

Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day

13 Oct 2021 06:45:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression

01 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021

28 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference

27 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress

20 Sep 2021 06:30:00 By Nasdaq GlobeNewswire